Onconetix Q2 net loss widens 20.9% to $2.87 million; revenue drops 83.9% to $17,120 vs year-ago quarter
ONCO•Second-quarter results
- Onconetix posted a Q2 net loss of $2.87 million, widening 20.9% from a year earlier.
- Revenue fell 83.9% to $17,120; gross margin slid 41.1 percentage points to 25.1%.
- Selling, general and administrative expenses rose 47.4% to $2.25 million, on higher accounting, legal and regulatory fees.
Clinical update and liquidity
- Proteomedix initiated the PRIME U.S. validation study with Labcorp for Proclarix, enrolling first participants toward up to 500 men.
- Cash totaled $5.9 million at June 30, 2026; management said the balance cannot fund operations through end-August 2027.
